Search
Now showing items 1-5 of 5
Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories.
(Wiley, 2017-06-01)
Over the past few years, treatment options for chronic hepatitis C virus (HCV) infection have evolved dramatically. The current approved interferon-free direct-acting antiviral (DAA) regimens have been shown to be safe and ...
Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories
(Wiley, 2017-01-20)
Over the past few years, treatment options for chronic hepatitis C virus (HCV) infection have evolved dramatically. The current approved interferon-free direct-acting antiviral (DAA) regimens have been shown to be safe and ...
Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
(Wiley, 2019-01-13)
Abstract
Background & Aims: Data from Europe and North America have been published re‐
garding the risk of developing hepatocellular carcinoma (HCC) after treatment with
direct antiviral agents (DAA). We proposed to ...
Simplified treatment of hepatitis C: another strategy to overcome the barriers to its elimination
(Medicina Buenos Aires, 2021-01)
Abstract in English, Spanish
The clinical management of hepatitis C virus (HCV) infection presents several challenges today. WHO's goal is to eliminate it by 2030. It is an ambitious goal and difficult to meet given the ...
'Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant
(Elsevier, 2021-11)
Abstract
Introductions and objectives: The introduction of direct-acting antiviral (DAA) agents promises to change dramatically the management of hepatitis C in kidney transplant recipients, a patient group where the ...